CA2813144C - Derives de cromene - Google Patents

Derives de cromene Download PDF

Info

Publication number
CA2813144C
CA2813144C CA2813144A CA2813144A CA2813144C CA 2813144 C CA2813144 C CA 2813144C CA 2813144 A CA2813144 A CA 2813144A CA 2813144 A CA2813144 A CA 2813144A CA 2813144 C CA2813144 C CA 2813144C
Authority
CA
Canada
Prior art keywords
4alkyl
independently represents
halogen
compound according
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2813144A
Other languages
English (en)
Other versions
CA2813144A1 (fr
Inventor
Balbino Jose Alarcon Sanchez
Angel Messeguer Peypoch
Antonio Morreale De Leon
Aldo Jorge Borroto Revuelta
Irene Azahara Arellano Rojo
Almudena Perona Requena
Esther Carrasco Romero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Publication of CA2813144A1 publication Critical patent/CA2813144A1/fr
Application granted granted Critical
Publication of CA2813144C publication Critical patent/CA2813144C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

L'invention concerne des dérivés de cromène représentés par la formule (I), les significations des différents substituants figurant dans la description. Ces composés sont utiles en tant qu'inhibiteurs de l'interaction TCR-Nkc dans des lymphocytes T.
CA2813144A 2010-09-28 2011-07-08 Derives de cromene Active CA2813144C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201031437A ES2379242B1 (es) 2010-09-28 2010-09-28 Derivados de cromeno.
ESP201031437 2010-09-28
PCT/ES2011/070506 WO2012042078A1 (fr) 2010-09-28 2011-07-08 Dérivés de cromène

Publications (2)

Publication Number Publication Date
CA2813144A1 CA2813144A1 (fr) 2012-04-05
CA2813144C true CA2813144C (fr) 2018-10-30

Family

ID=45892008

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2813144A Active CA2813144C (fr) 2010-09-28 2011-07-08 Derives de cromene

Country Status (17)

Country Link
US (1) US9120764B2 (fr)
EP (1) EP2623503B1 (fr)
JP (1) JP5894164B2 (fr)
KR (1) KR101800919B1 (fr)
CN (1) CN103189367B (fr)
AU (1) AU2011310078B2 (fr)
BR (1) BR112013007073B1 (fr)
CA (1) CA2813144C (fr)
DK (1) DK2623503T3 (fr)
ES (1) ES2379242B1 (fr)
HK (1) HK1186727A1 (fr)
HR (1) HRP20151378T1 (fr)
HU (1) HUE025731T2 (fr)
MX (1) MX342960B (fr)
PL (1) PL2623503T3 (fr)
PT (1) PT2623503E (fr)
WO (1) WO2012042078A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201602982YA (en) * 2013-10-17 2016-05-30 Abbvie Deutschland Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
ES2534318B1 (es) 2013-10-18 2016-01-28 Artax Biopharma Inc. Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck
ES2534336B1 (es) * 2013-10-18 2016-01-28 Artax Biopharma Inc. Derivados de cromeno como inhibidores de la interacción TCR-Nck
US9968604B2 (en) 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
IL301120A (en) * 2018-02-27 2023-05-01 Artax Biopharma Inc A history of novel chromium as TCR–NCK interaction inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008217A2 (fr) * 2000-07-21 2002-01-31 Chugai Seiyaku Kabushiki Kaisha DERIVES DE LA COUMARINE UTILISES COMME INHIBITEUR DU TNF$g(a)
WO2005058834A2 (fr) * 2003-12-12 2005-06-30 Wyeth Quinolines convenant pour le traitement de maladies cardio-vasculaires
CA2938241A1 (fr) * 2006-07-06 2008-01-10 Cytovia, Inc. 4-aryl-chromene substitue en tant qu'activateur de capsases et inducteur d'apoptose ainsi que comme agent anti-vasculaire, et utilisation
ES2331451B1 (es) * 2008-06-30 2010-10-21 Consejo Superior De Investigaciones Cientificas (Csic) Inmunosupresor basado en la interrupcion de la interaccion tcr-nck.
AU2009323259A1 (en) * 2008-12-05 2011-06-23 Astellas Pharma Inc. 2H-chromene compound and derivative thereof

Also Published As

Publication number Publication date
CN103189367A (zh) 2013-07-03
US9120764B2 (en) 2015-09-01
HRP20151378T1 (hr) 2016-01-15
AU2011310078B2 (en) 2016-12-15
EP2623503A4 (fr) 2014-03-05
DK2623503T3 (en) 2016-01-11
WO2012042078A1 (fr) 2012-04-05
KR101800919B1 (ko) 2017-11-23
PT2623503E (pt) 2016-01-26
AU2011310078A1 (en) 2013-04-11
ES2379242B1 (es) 2013-03-04
MX2013003498A (es) 2013-05-20
CN103189367B (zh) 2016-06-08
HK1186727A1 (zh) 2014-07-04
JP5894164B2 (ja) 2016-03-23
ES2379242A1 (es) 2012-04-24
KR20130141481A (ko) 2013-12-26
BR112013007073A2 (pt) 2020-04-28
CA2813144A1 (fr) 2012-04-05
EP2623503B1 (fr) 2015-09-23
RU2013117924A (ru) 2014-11-10
MX342960B (es) 2016-10-18
HUE025731T2 (en) 2016-05-30
JP2013537899A (ja) 2013-10-07
PL2623503T3 (pl) 2016-04-29
US20140005247A1 (en) 2014-01-02
BR112013007073B1 (pt) 2021-11-16
EP2623503A1 (fr) 2013-08-07

Similar Documents

Publication Publication Date Title
JP7033141B2 (ja) メニン－ｍｌｌ相互作用の縮合二環式阻害剤
CA3037986C (fr) Modulateur de regulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procedes de traitement et procede de fabrication du modulateur
EP2300472B1 (fr) Mimétiques de glucocorticoïdes, leurs procédés de fabrication, compositions pharmaceutiques et leurs utilisations
US7214690B2 (en) Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
JP2010523522A (ja) Ｊａｋ３阻害剤としてのピロロピリミジン誘導体
CA2770932C (fr) N-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines substituees
EP2258704A1 (fr) Synthese d'inhibiteurs d'imidazo-oxazole et d'imidazothiazole de la map kinase p38
CA2813144C (fr) Derives de cromene
CA3147422A1 (fr) Inhibiteurs de kinases dependantes des cyclines
JP2021532100A (ja) さらなる置換トリアゾロキノキサリン誘導体
CN116874503A (zh) 一种高活性的hpk1激酶抑制剂
EP3696178B1 (fr) Composé hétérocyclique et son application en médecine
EP2810942B1 (fr) Dérivé de paroxétine
EP4206197A1 (fr) Procédé de préparation d'un nouvel inhibiteur de protéine kinase liée à rho et d'un intermédiaire dans le procédé de préparation
RU2574164C2 (ru) Производные хромена
CN116874465B (zh) 嘧啶类化合物及其应用
CN116854687A (zh) Hpk1激酶抑制剂化合物
WO2010094721A1 (fr) Dérivés de pipéridine-pyrimidine comme antagonistes des récepteurs histaminiques h4
Gan The Design of Novel DCB-3503 Analogues: Ligand-Based and Structure-Based Approaches

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160708